Literature DB >> 11065173

Pimobendan inhibits the activation of transcription factor NF-kappaB: a mechanism which explains its inhibition of cytokine production and inducible nitric oxide synthase.

A Matsumori1, Y Nunokawa, S Sasayama.   

Abstract

Pimobendan, an inhibitor of phosphodiesterase III with calcium sensitizing properties, inhibits the production of cytokines and nitric oxide. In the present study, the effects of pimobendan and other inotropic agents on the activation of transcription factor NF-kappaB were examined. Pimobendan significantly decreased the expression of luciferase protein in A549 cells transfected with the NF-kappaB reporter plasmid, stimulated with interleukin (IL)-1beta, tumor necrosis factor-alpha, or phorbol 12-myristate 13 acetate. However, high concentrations of amrinone, vesnarinone, or NKH 477 decreased promoter activity only slightly. Electrophoretic mobility shift assay also showed inhibition of NF-kappaB activation by pimobendan. Pimobendan possesses the unique property of inhibiting NF-kappaB, which may be independent of phosphodiesterase inhibition.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11065173     DOI: 10.1016/s0024-3205(00)00834-1

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

1.  N-Pyrazoloyl and N-thiopheneacetyl hydrazone of isatin exhibited potent anti-inflammatory and anti-nociceptive properties through suppression of NF-κB, MAPK and oxidative stress signaling in animal models of inflammation.

Authors:  Sara Zeeshan; Muhammad Naveed; Adnan Khan; Ayesha Atiq; Maryam Arif; Muhammad Naeem Ahmed; Yeong Shik Kim; Salman Khan
Journal:  Inflamm Res       Date:  2019-05-11       Impact factor: 4.575

2.  Pharmaceutical and nutraceutical effects of Pinus pinaster bark extract.

Authors:  S Iravani; B Zolfaghari
Journal:  Res Pharm Sci       Date:  2011-01

3.  Pimobendan Inhibits HBV Transcription and Replication by Suppressing HBV Promoters Activity.

Authors:  Si-Yu Yuan; Hai-Bo Yu; Zhen Yang; Yi-Ping Qin; Ji-Hua Ren; Sheng-Tao Cheng; Fang Ren; Betty Yuen Kwan Law; Vincent Kam Wai Wong; Jerome P L Ng; Yu-Jiao Zhou; Xin He; Ming Tan; Zhen-Zhen Zhang; Juan Chen
Journal:  Front Pharmacol       Date:  2022-06-03       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.